Dr Reddy’s Labs announces launch of Bortezomib injection in US market

Hyderabad, July 27 : Dr. Reddy’s Laboratories Limited on Wednesday announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent 12 months ending in May 2022 according to IQVIA Health, Hyderabad based Pharma giant said in a release here.
Dr. Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.


Please enter your comment!
Please enter your name here